Dr. Reddy's Laboratories
Indian integrated pharmaceutical company
RDY NYSE
ISIN US2561352038 SEC CIK 1135951 LEI 335800OVDPY3DVZR2798
Follow Dr. Reddy's Laboratories
Weekly email: filings, results
EPS, diluted
-
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | INR 325.5B | INR 56.5B |
| FY24 | INR 279.2B | INR 55.7B |
| FY23 | INR 245.9B | INR 45.1B |
| FY22 | INR 214.4B | INR 23.6B |
| FY21 | INR 189.7B | INR 17.2B |
| FY20 | INR 174.6B | INR 19.5B |
| FY19 | INR 153.9B | INR 18.8B |
| FY18 | INR 142B | INR 9.8B |
| FY17 | INR 140.8B | INR 12B |
| FY16 | INR 154.7B | INR 20B |
| FY15 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 58.5% | 22.1% | 17.4% |
| FY24 | 58.6% | 24.3% | 19.9% |
| FY23 | 56.7% | 23.2% | 18.3% |
| FY22 | 53.1% | 13.7% | 11% |
| FY21 | 54.3% | 12.8% | 9.1% |
| FY20 | 53.8% | 9.2% | 11.2% |
| FY19 | 54.2% | 13.6% | 12.2% |
| FY18 | 53.7% | 8.4% | 6.9% |
| FY17 | 55.6% | 9.6% | 8.5% |
| FY16 | 59.6% | 19.1% | 12.9% |
| FY15 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | INR 18.9B |
| FY24 | INR 29B |
| FY23 | INR 47.6B |
| FY22 | INR 13.4B |
| FY21 | INR 26B |
| FY20 | INR 25B |
| FY19 | INR 21.7B |
| FY18 | INR 8.7B |
| FY17 | INR 9.2B |
| FY16 | INR 29.2B |
| FY15 | - |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY25 | INR 6.7B | - |
| FY24 | INR 6.6B | - |
| FY23 | INR 5B | - |
| FY22 | INR 4.1B | INR 0 |
| FY21 | INR 4.1B | INR 1.2B |
| FY20 | INR 3.9B | INR 474M |
| FY19 | INR 4B | INR 0 |
| FY18 | INR 4B | INR 0 |
| FY17 | INR 3.4B | INR 15.7B |
| FY16 | INR 4.1B | INR 0 |
| FY15 | - | - |
- Dr. Reddy's Laboratories
- Healthcare median
Show the numbers
| Year | Dr. Reddy's Laboratories | Healthcare median |
|---|---|---|
| FY25 | 17.4% | −30.6% |
| FY24 | 19.9% | −47% |
| FY23 | 18.3% | −58% |
| FY22 | 11% | −80.4% |
| FY21 | 9.1% | −71.9% |
| FY20 | 11.2% | −62.2% |
| FY19 | 12.2% | −46.3% |
| FY18 | 6.9% | −49.6% |
| FY17 | 8.5% | −45.9% |
| FY16 | 12.9% | −36% |
| FY15 | - | −38.4% |